Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (587)	3/10/2005 12:29:02 AM
From: Sam Citron	Respond to of 946

Wells Fargo "Fireside Chat" (3/1-2/05) Notes: "Xyotax, unlike Taxol, is a ten minute infusion instead of a three hour infusion" Bianco 4:10 "Because the side effect profile is dramatically different in the phase 1 2 effort, these patients wont have hair loss." Bianco 4:25 "Even if we dont meet primary endpoint ... we would argue to the Agency that the unmet medical need is a doublet therapy that you can dose aggressively to get improved survival for PS2s without increased toxicity as a consequence of it...It will be a win on neutropenia, sepsis, etc, and a win on QOL." Bianco ~ 44:00 One thing he kept repeating was that the test would validate that more is better. I guess what he meant was more cycles at lower dosages. Sam

To: Ian@SI who wrote (587)	3/10/2005 1:13:05 AM
From: tuck	Read Replies (1) \| Respond to of 946

Thanks for the reminder. 175 PS2 patients out 850. Better odds, perhaps, and one would think with 850 patients that power will not be an issue. This might bolster my case for Stellar 2 having better chances than Stellar 3. Then again, maybe it doesn't. They might prove superiority, but not by a wide enough margin. They were gunning for a 30% difference in survival in Stellar 3, weren't they? Is that the case in these other two? Anyhow, Miljenko's call is looking pretty good after all. Cheers, Tuck